DIABETIC NEPHROPATHY MADRAS DIABETES RESEARCH FOUNDATION, Gopalapuram, Chennai DIRECTOR & DIABETOLOGIST Dr.Mohan’s DIABETES SPECIALITIES CENTRE Dr. Mohan’s.

Slides:

Advertisements

Similar presentations

The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.

Advertisements

William Vega-Ocasio MD. Internal Medicine - Nephrology

Dinkar Kaw, M.D., Division of Nephrology

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.

Prepared by D. Chaplin Chronic Renal Failure. Prepared by D. Chaplin Chronic Renal Failure Progressive, irreversible damage to the nephrons and glomeruli.

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.

The PREVEND Study: Screening for micro-albuminuria

DIABETIC NEPHROPATHY MAY 2013 DR RAMESH B NAIK FRCP.

Diabetic Nephropathy. Diabetic Nephropathy A clinical syndrome DM + Persistent albuminuria, Worsening proteinuria, Hypertension & progressive renal failure.

Proteinuria as a Surrogate Outcome in Chronic Kidney Disease Early Diabetes – Microalbuminuria (MA) Type 2 Diabetes in American Indians Robert G Nelson,

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.

A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Lesley Stevens MD Tufts-New England Medical Center

Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.

Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.

RENAL DISEASE IN DIABETES

Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.

Copyright ©2000 BMJ Publishing Group Ltd. Stratton, I. M et al. BMJ 2000; 321:

Diabetic Nephropathy in the Adolescent Age Group Henry Rodriguez, M.D. Associate Professor of Pediatrics Indiana University School of Medicine Director,

Aminoglycoside-Induced Acute Tubular Necrosis PHCL 442 Lab Discussion 2 Raniah Al-Jaizani M.Sc.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

La gestione del paziente diabetico: bisogni, percorsi e strumenti Metodi per lo studio della nefropatia Giuseppe Penno Dipartimento di Medicina Clinica.

Systemic diseases and the kidney Dr I.Sagiv M.D Nephrology & Hypertension services Hadassah-Hebrew university medical center Jerusalem.

Nephrology Core Curriculum Diabetic Nephropathy. Diabetic Nephropathy 35% of all the patients enrolled in the Medicare ESRD program –63% are type II $2.

2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,

ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA.

Hypertension Control and Progression of Renal Disease

WHAT IS DRIVING THE DIABETES EPIDEMIC IN INDIA? WHAT IS DRIVING THE DIABETES EPIDEMIC IN INDIA? MADRAS DIABETES RESEARCH FOUNDATION, Gopalapuram, Chennai.

Predicting Progression in Diabetic Nephropathy: New Biomarker: sTNFR1* Circulating soluble Tumor Necrosis Factor Receptor 1.

Kidney Disorders By Amir Ashkan Ashrafian M.D.  A spectrum of different pathophysiologic processes associated with abnormal kidney function and a progressive.

SCREENING FOR RETINOPATHY & NEPHROPATHY 1 Prof.V.Mohan.,M.D.,Ph.D.,D.Sc. DIRECTOR M.V.DIABETES SPECIALITIES CENTRE, PROFESSOR OF INTERNATIONAL HEALTH UNIVERSITY.

Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function Featured Article: Elif I. Ekinci, P.H.D.,

Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Decline in Estimated Glomerular Filtration Rate and.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Preventive Measures Infection & Delayed Wound Healing Frequent dental visits to assess plaque control Risk assessment profiles to identify risk factors.

Section 4: Managing progression of CKD

Robert C. Stanton, MD American Journal of Kidney Diseases

Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy Kantima Phisitkul, MD, Khaled Hegazy, MD, Temduang.

Dr. Mohammad Alkhowaiter, MD Consultant Nephrologist

Estimated GFR in Diabetes

The percentage of subjects with de novo development of renal function impairment (GFR

These slides highlight an educational report from a satellite symposium presented at the Annual Scientific Meeting of the Canadian Society of Internal.

Management of hypertension in patients with chronic kidney disease

Jessica W. Weiss, MD, Eric S. Johnson, PhD, Amanda Petrik, MS, David H

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Update on Diabetic Nephropathy: Core Curriculum 2018

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion Matthew.

Diabetic nephropathy 2018 Dr. Lawrence J. Smith Chief, Renal Division

Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

Robert C. Stanton, MD American Journal of Kidney Diseases

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Manjula Kurella Tamura, Kristine Yaffe Kidney International

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Update on Diabetic Nephropathy: Core Curriculum 2018

Dr. Mohammad Alkhowaiter, MD Consultant Nephrologist

Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.

Michael R. Lattanzio, Matthew R. Weir Kidney International

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.

Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)

Lipoprotein abnormalities in diabetic nephropathy

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

Presentation transcript:

DIABETIC NEPHROPATHY MADRAS DIABETES RESEARCH FOUNDATION, Gopalapuram, Chennai DIRECTOR & DIABETOLOGIST Dr.Mohan’s DIABETES SPECIALITIES CENTRE Dr. Mohan’s DIABETES SPECIALITIES CENTRE, Anna Nagar, Chennai Dr. Mohan’s DIABETES SPECIALITIES CENTRE, Gopalapuram, Chennai Dr. Mohan’s DIABETES SPECIALITIES CENTRE, Jubilee Hills, Hyderabad India Chennai (Formerly Madras) Hyderabad Dr.Ranjit Unnikrishnan I., M.D.,

DIABETIC NEPHROPATHY – MAGNITUDE OF THE PROBLEM Most important cause of morbidity and mortality in Type 1 diabetes – progression is faster 50% with clinical nephropathy reach ESRD by 10 years 75% with clinical nephropathy reach ESRD by 20 years In Type 2 diabetes mellitus progression is slower – 20% reach ESRD About 25 – 50% of all cases of ESRD is due to diabetes ? Racial factors ? Indians / Blacks more susceptible High economic burden on society

NATURAL HISTORY OF NEPHROPATHY IN TYPE 1 DIABETES Stage of hyperfiltration Micro albuminuria Macro albuminuria Azotemia (Renal failure) End stage Renal disease yrs 1 yrs yrs Normo albuminuria

MICROALBUMINURIA AND DIABETIC NEPHROPATHY STAGES Stages Designation Structural GFR UAE BP changes Stage I Hyperfiltration Glomerular = 150 may N or Hypertrophy Hypertrophy be  Stage II Normo  BM  20% - N N albuminuria thickness 30% Stage III Microalbuminuria Further  BM  GFR  thickness  g/min -3mm of Hg

MICROALBUMINURIA AND DIABETIC NEPHROPATHY STAGES Stages Designation Structural GFR UAE BP changes Stage Overt Clear and  >200 Hyper- IV Proteinuria Pronounced  g/min tension abnormalities Dipstick positive Stage End stage Glomerular  >200 V Renal closure  g/min Hyper- Disease tension

PREVALENCE OF PROTEINURIA CLINIC BASED STUDY ON 1848 TYPE 2 DIABETIC INDIVIDUALS n=1848 Mohan V et al, Postgrad Med J. 2000;76: